MGC Pharmaceuticals: plant-based treatment to address unmet medical needs
The phytomedicine group has been the top riser in London on Thursday
Company
Argent BioPharma Ltd
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 7 of 8
MGC Pharma inks US deal worth at least US$24mln
The supply and distribution tie-up is with AMC Holdings
MGC Pharmaceuticals reports record quarterly sales
The company's co-founder Roby Zomer said the results meant the group "remains on a strong operational and commercial growth trajectory going into the new financial year"
MGC Pharmaceuticals applies for cannabinoid brain disorder patent
"The acceptance of this patent could be transformational for patients who need treatment and therapeutic relief from neurological diseases"
Archive
Proactive news headlines: MGC Pharmaceuticals, Westminster Group, Voyager Life, Coro Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
MGC Pharmaceuticals gets phase III trial of lead drug underway
CimetrA will be used to treat hospitalised COVID-19 patients
MGC Pharmaceuticals epilepsy product added to Primary Care Reimbursement Service making it free of charge for Irish patients
A product formulated by MGC Pharmaceuticals that combats drug-resistant epilepsy will be fully subsidised for patients by Ireland’s health system.
MGC Pharmaceuticals appoints David Lim as joint company secretary
The European-based company develops and supplies affordable standardised phytocannabinoid-derived medicines to patients globally.
Archive
Proactive news headlines: MGC Pharmaceuticals, Bango, Cellular Goods, Gaming Realms...
A glance at some of the day's highlights from the Proactive Investors newswire
MGC Pharmaceuticals progresses clinical trial planning for CimetrA, CannEpil and CogniCann
All three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021.
MGC Pharmaceuticals submits patent application for CimetrA to European IP Office
CimetrATM has been designed for multiple therapeutic applications including acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy.
MGC Pharma submits patent application for virus symptoms treatment
The bio-pharma firm said it expects the patent to be issued from the Slovenian Intellectual Property Office within the next 12 months
Proactive news headlines: MGC Pharmaceuticals, Sensyne Health, Tiziana Life Sciences, San Leon Energy...
A glance at some of the day's highlights from the Proactive Invesors newswire
MGC Pharmaceuticals shares boosted by latest ArtemiC results in COVID-19 study
The mechanism of action of ArtemiC is focused on the anti-inflammatory effect and prevention of cytokine storm
UK cannabis industry growing like a weed, report reveals
CBD sales totalled £690mln in the year under review, up almost a third
MGC Pharmaceuticals in trading halt pending announcement by the company on ArtemiC
Its securities will remain halted until the start of normal trading on Monday, May 10, 2021, or until an announcement is released to the market.
MGC Pharmaceuticals shares rise in London as Swiss distributor orders more COVID-19 recovery support supplements
“Receiving a second order on such a large scale from Swiss PharmaCan demonstrates the increasing demand for our product ArtemiC Rescue, and its associated benefits,” said Roby Zomer.
MGC Pharmaceuticals wins A$1 million order for ArtemiC Rescue
Phase 2 trials have shown ArtemiC’s ability to reduce symptoms and pain associated with COVID-19 and achieve faster clinical improvements.
MGC Pharmaceuticals shares rise in London as distributor seeks Canadian approval for ArtemiC
The natural health product has been seen to be effective in trials as a support recovery for COVID-19 patients.
MGC Pharmaceuticals' North American distribution partner submits application to Health Canada for ArtemiC™
Glow LifeTech has exclusive rights to market, sell and distribute ArtemiC™ in Canada, USA, Mexico and all Caribbean countries as a food supplement (nutraceutical, dietary supplement, natural health product).